A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Trial Identifier: 6070-002
Sponsor: MSD
Collaborator:
Daiichi Sankyo
Start Date: March 2025
Primary Completion Date: October 2028
Study Completion Date: October 2028
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English

Trial Locations

Country Location
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Ramat Gan, N/A, Israel, 5265601